explore -WSS

explore

author：comprehensive 2025-09-05 11:23:55 - browse：894

Joe Biden in 2016. -- first opinion coverage from STAT — President Joe Biden Elise Amendola/AP

WASHINGTON — The latest phase of President Biden’s Cancer Moonshot initiative leaves open a few questions on how Congress might move forward with the program.

Since its launch in 2016, the federally funded cancer moonshot program has spurred thousands of scientific publications, 49 clinical trials, and more than 30 patent filings, according to a new report from the Congressional Research Service, the nonpartisan research arm of Congress.

The next phase of the cancer moonshot, according to Biden and his administration, is meant to emphasize cancer screening, prevention, and equitable treatment. The updated plan also seeks to speed progress on treatments for rare and childhood cancers, and it calls for supporting patients, survivors, and caregivers. The Advanced Research Projects Agency for Health (ARPA-H), a new agency tasked with taking big risks on biomedical and health technology, is also committing $240 million to cancer-related research and investing in new data-sharing platforms and a nationwide network for clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Roche’s Alnylam deal shows drug firms interested in heart drugs

explore

WSS

Addiction doctors spar with methadone clinics over legislation

Dark money group runs ads on China biotech bill

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Latest bird flu infection made farmworker sicker than earlier cases

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Startling documents reveal new facets of Sacklers' opioid empire

knowledge

explore

explore

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Startling documents reveal new facets of Sacklers' opioid empire

United colonoscopy coverage change 'may cost lives,' doctors say

Truvian presents data for its desktop blood

Psychedelics group wrestles with new pharma identity

Childbirth

Bright Health sells Medicare Advantage business to Molina

Insmed lung disease drug hits target in key Phase 3 trial

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

explore

The battle over 'scope creep' and who gets to be called 'doctor'

What to watch for from Zogenix and Amicus clinical trials

The battle over 'scope creep' and who gets to be called 'doctor'

Health insurers say they are turning to AI to cut costs, improve care

What will save rural psychiatry services? Higher Medicaid payments

What causes rare myocarditis in young men after Covid vaccines?

explore

focus

leisure time

explore